Back

Study to evaluate the effect of balcinrenone/dapagliflozin in patients with heart failure and impaired kidney function (BalanceD-HF): background and design

31 August 2026 (09:50 - 10:00)
Organised by: Logo
Congress Presentation Part of: Multi-organ frailty: liver fibrosis, kidney, and left atrial remodelling Comorbidities ESC Professional Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor John R Teerlink

San Francisco Veterans Affairs Medical Centre, San Francisco (United States of America)

5 More presentations in this session

Presentation thumbnail
Frailty redefines the prognostic value of multimorbidity in heart failure
Doctor V. Copeland (Ramat Gan, IL)
Abstract Slides Video
Presentation thumbnail
Liver fibrosis in heart failure patients is associated with adverse outcomes, signs of congestion, and ⍺v integrin-related processes: insights from BIOSTAT-CHF
Mr M. Tow (Dundee, GB)
Abstract Slides Video
Presentation thumbnail
Performance of an artificial intelligence-based smartphone application to assess frailty in older patients with heart failure
Mr S. Tahara (Sapporo, JP)
Abstract Slides Video
Presentation thumbnail
Metabolomic signature predicting ejection fraction recovery in recent-onset dilated cardiomyopathy
Doctor Y. Xie (CN)
Abstract Slides Video
Presentation thumbnail
Left atrial remodeling and microstructural damage in the internal capsule in heart failure: a comparison based on left atrial maximum volume index stratification
Doctor C. Pan (Zhuhai, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Multi-organ frailty: liver fibrosis, kidney, and left atrial remodelling
Video

The Event

Event poster

ESC Congress 2026

31 August 2026 09:50 CET
You may be interested in
thumbnail
Congress Session
Transforming heart failure with next-generation therapies and mechanisms
31 August 2026
thumbnail
Congress Presentation
Effect of dapagliflozin on left ventricular mass in patients with kidney failure receiving maintenance hemodialysis: Primary results from the DAPA-HD trial
29 August 2026
thumbnail
Congress Presentation
SGLT2 inhibitors and anti-aldosterone agent combinations
18 May 2025
thumbnail
Congress Presentation
The DIALY-MRA trial: a randomised comparison of finerenone versus spironolactone in patients on maintenance dialysis - a 3-month biomarker and safety study
28 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources